Browse IL18

Summary
SymbolIL18
Nameinterleukin 18
Aliases IGIF; IL1F4; IL-1g; IL-18; interferon-gamma-inducing factor; interleukin 18 (interferon-gamma-inducing facto ......
Chromosomal Location11q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00340 Interleukin-1 / 18
Function

Augments natural killer cell activity in spleen cells and stimulates interferon gamma production in T-helper type I cells.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001787 natural killer cell proliferation
GO:0001819 positive regulation of cytokine production
GO:0001866 NK T cell proliferation
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002828 regulation of type 2 immune response
GO:0002830 positive regulation of type 2 immune response
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0007159 leukocyte cell-cell adhesion
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0010742 macrophage derived foam cell differentiation
GO:0010743 regulation of macrophage derived foam cell differentiation
GO:0010744 positive regulation of macrophage derived foam cell differentiation
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0017038 protein import
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030101 natural killer cell activation
GO:0030217 T cell differentiation
GO:0030431 sleep
GO:0031349 positive regulation of defense response
GO:0031503 protein complex localization
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0032103 positive regulation of response to external stimulus
GO:0032147 activation of protein kinase activity
GO:0032148 activation of protein kinase B activity
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032496 response to lipopolysaccharide
GO:0032602 chemokine production
GO:0032604 granulocyte macrophage colony-stimulating factor production
GO:0032609 interferon-gamma production
GO:0032616 interleukin-13 production
GO:0032620 interleukin-17 production
GO:0032623 interleukin-2 production
GO:0032645 regulation of granulocyte macrophage colony-stimulating factor production
GO:0032649 regulation of interferon-gamma production
GO:0032660 regulation of interleukin-17 production
GO:0032725 positive regulation of granulocyte macrophage colony-stimulating factor production
GO:0032729 positive regulation of interferon-gamma production
GO:0032740 positive regulation of interleukin-17 production
GO:0032814 regulation of natural killer cell activation
GO:0032816 positive regulation of natural killer cell activation
GO:0032817 regulation of natural killer cell proliferation
GO:0032819 positive regulation of natural killer cell proliferation
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033002 muscle cell proliferation
GO:0033157 regulation of intracellular protein transport
GO:0033674 positive regulation of kinase activity
GO:0034103 regulation of tissue remodeling
GO:0034105 positive regulation of tissue remodeling
GO:0034504 protein localization to nucleus
GO:0035655 interleukin-18-mediated signaling pathway
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0042033 chemokine biosynthetic process
GO:0042088 T-helper 1 type immune response
GO:0042089 cytokine biosynthetic process
GO:0042092 type 2 immune response
GO:0042093 T-helper cell differentiation
GO:0042094 interleukin-2 biosynthetic process
GO:0042095 interferon-gamma biosynthetic process
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042104 positive regulation of activated T cell proliferation
GO:0042107 cytokine metabolic process
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0042231 interleukin-13 biosynthetic process
GO:0042253 granulocyte macrophage colony-stimulating factor biosynthetic process
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0042345 regulation of NF-kappaB import into nucleus
GO:0042346 positive regulation of NF-kappaB import into nucleus
GO:0042348 NF-kappaB import into nucleus
GO:0042503 tyrosine phosphorylation of Stat3 protein
GO:0042509 regulation of tyrosine phosphorylation of STAT protein
GO:0042516 regulation of tyrosine phosphorylation of Stat3 protein
GO:0042517 positive regulation of tyrosine phosphorylation of Stat3 protein
GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
GO:0042632 cholesterol homeostasis
GO:0042692 muscle cell differentiation
GO:0042990 regulation of transcription factor import into nucleus
GO:0042991 transcription factor import into nucleus
GO:0042993 positive regulation of transcription factor import into nucleus
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043372 positive regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043491 protein kinase B signaling
GO:0044744 protein targeting to nucleus
GO:0045064 T-helper 2 cell differentiation
GO:0045445 myoblast differentiation
GO:0045580 regulation of T cell differentiation
GO:0045582 positive regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045622 regulation of T-helper cell differentiation
GO:0045624 positive regulation of T-helper cell differentiation
GO:0045628 regulation of T-helper 2 cell differentiation
GO:0045630 positive regulation of T-helper 2 cell differentiation
GO:0045661 regulation of myoblast differentiation
GO:0045662 negative regulation of myoblast differentiation
GO:0045785 positive regulation of cell adhesion
GO:0045860 positive regulation of protein kinase activity
GO:0046006 regulation of activated T cell proliferation
GO:0046425 regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046633 alpha-beta T cell proliferation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046635 positive regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046638 positive regulation of alpha-beta T cell differentiation
GO:0046640 regulation of alpha-beta T cell proliferation
GO:0046641 positive regulation of alpha-beta T cell proliferation
GO:0046651 lymphocyte proliferation
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048514 blood vessel morphogenesis
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0048771 tissue remodeling
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050755 chemokine metabolic process
GO:0050798 activated T cell proliferation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051132 NK T cell activation
GO:0051133 regulation of NK T cell activation
GO:0051135 positive regulation of NK T cell activation
GO:0051140 regulation of NK T cell proliferation
GO:0051142 positive regulation of NK T cell proliferation
GO:0051147 regulation of muscle cell differentiation
GO:0051148 negative regulation of muscle cell differentiation
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051222 positive regulation of protein transport
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0055088 lipid homeostasis
GO:0055090 acylglycerol homeostasis
GO:0055092 sterol homeostasis
GO:0070328 triglyceride homeostasis
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0070673 response to interleukin-18
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071351 cellular response to interleukin-18
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071593 lymphocyte aggregation
GO:0090077 foam cell differentiation
GO:0090316 positive regulation of intracellular protein transport
GO:0097696 STAT cascade
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1902593 single-organism nuclear import
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903533 regulation of protein targeting
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1903829 positive regulation of cellular protein localization
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904892 regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
GO:1904951 positive regulation of establishment of protein localization
GO:2000514 regulation of CD4-positive, alpha-beta T cell activation
GO:2000516 positive regulation of CD4-positive, alpha-beta T cell activation
Molecular Function GO:0005125 cytokine activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04621 NOD-like receptor signaling pathway
hsa04623 Cytosolic DNA-sensing pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-448706: Interleukin-1 processing
R-HSA-6783783: Interleukin-10 signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-449147: Signaling by Interleukins
Summary
SymbolIL18
Nameinterleukin 18
Aliases IGIF; IL1F4; IL-1g; IL-18; interferon-gamma-inducing factor; interleukin 18 (interferon-gamma-inducing facto ......
Chromosomal Location11q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL18 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL18 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26755531MelanomaPromote immunityThe results demonstrated that IL18 enhanced therapeutic effects of immune checkpoint blockade against peritoneal dissemination of carcinoma or tail vein injection metastasis of melanoma through accumulation of pre-mNK cells, memory-type CD8(+) T cells, and suppression of CD4(+)CD25(+)Foxp3(+) T cells.
26384545Colorectal CarcinomaPromote immunity (NK cell function)Here, we show that mice deficient in Nlrp3 inflammasome components had exacerbated liver colorectal cancer metastatic growth, which was mediated by impaired interleukin-18 (IL-18) signaling. Control of tumor growth was independent of differential cancer cell colonization or proliferation, intestinal microbiota effects, or tumoricidal activity by the adaptive immune system.
25600646Hepatocellular CarcinomaInhibit immunity (T cell function)TLR2 limits development of hepatocellular carcinoma by reducing IL18-mediated immunosuppression. IL18 production was mediated by caspase-8 insofar as the decrease in its silencing was sufficient to attenuate levels of mature IL18 in Tlr2(-/-) mice.
25362180MelanomaInhibit immunity (T cell function)IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells.
25329698LymphomaPromote immunity (NK cell function)Here, we found that treatments with IL-12 and IL-18 or with a mutant form of IL-2 (the "superkine" called H9) provided substantial therapeutic benefit for mice specifically bearing MHC class I-deficient tumors, but these treatments were ineffective for mice with matched MHC class I+ tumors. Cytokine efficacy was linked to the reversal of the anergic state of NK cells that specifically occurred in MHC class I-deficient tumors, but not MHC class I+ tumors.
27655849Acute Myeloid LeukemiaPromote immunity; Essential for immunotherapyCytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Cytokine-induced memory-like NK cells differentiate after a brief preactivation with interleukin-12 (IL-12), IL-15, and IL-18 and exhibit enhanced responses to cytokine or activating receptor restimulation for weeks to months after preactivation.
18442334Gastric CarcinomaIncrease the efficacy of immunotherapyLevels of interleukin-18 are markedly increased in Helicobacter pylori-infected gastric mucosa among patients with specific IL18 genotypes. Biopsy specimens from 128 patients (56 with nonulcer dyspepsia, 28 with gastric ulcers, 28 with duodenal ulcers, and 16 with gastric cancer) were examined; 96 patients had H. pylori infection. IL-18 levels were markedly up-regulated in mucosa infected with H. pylori (P < .001), whereas IL-12 and IFN-gamma levels were independent of H. pylori status. IL18 genotype might be a marker for predicting the effects of eradication therapy.
16517714NeuroblastomaPromote immunity (T and NK cell function); essential for immunotherapyWith the transduction of IL-12 and IL-18 genes into the fusion cells (fusion/IL-12/IL-18), the level of IFN-gamma increased more than five times that of other fusion groups. In addition, NK cell activity and CTL activity increased significantly compared with that of mixture/LacZ, fusion/LacZ, DC/LacZ, or C1300/LacZ.
19688743MelanomaPromote immunity (T cell function)Gadd45b, a signaling molecule highly up-regulated during Th1 type responses, is studied for its role in limiting tumor growth. Mouse B16 melanoma cells implanted into Gadd45b(-/-) mice grew faster than those in WT or Gadd45b(+/-) littermate controls. The defect of Gadd45b(-/-) mice in tumor immunosurveillance was attributed to the reduced expression of IFN-gamma, granzyme B, and CCR5 in Gadd45b(-/-) CD8(+) T cells at the tumor site. Activation of p38 MAP kinase, but not ERK or JNK, by either TCR-stimuli or IL-12 and IL-18 is diminished in Gadd45b(-/-) CD8(+) T cells, resulting in reduced production of IFN-gamma.
16778218MelanomaPromote immunity (T cell function)In vivo depletion assay revealed that the antitumor effect of B16/IL-23 was mainly mediated by CD8+ T cells and IFN-gamma whereas that of B16/IL-27 mainly involved natural killer cells and was independent of IFN-gamma. We also found that antitumor effects of B16/IL-23 and B16/IL-27 were synergistically enhanced by treatment with IL-18 and IL-12, respectively. Our data support that IL-23 and IL-27 might play a role in future cytokine-based immunotherapy against poorly immunogenic tumors.
16651448LeukemiaPromote immunity (T cell function)The cytokine interleukin (IL)-12 promotes CD8(+) T-cell cytotoxicity and, with IL-18, synergistically up-regulates IFN-gamma release. We have shown that culturing CD8(+) T cells ex vivo with IL-12 and IL-18 enhanced antitumor responses in vivo and in vitro using a model of C1498/ovalbumin, a murine acute myeloid leukemia cell line expressing the antigen ovalbumin. Maximal IFN-gamma release occurred after T-cell culture with IL-12 and IL-18. Tumor-specific in vitro cytotoxicity was enhanced by IL-12, unaffected by addition of IL-18, and abrogated in perforin-deficient T cells irrespective of cytokine exposure.
29599908Pancreatic ductal adenocarcinoma; melanoma; colon carcinomaInhibit immunity immunotherapy targetOur results show that IL-18 and PD-1/PD-L1 could be therapeutic targets in pancreatic cancer.
29572232Plasma Cell MyelomaInhibit immunity (T cell function); decrease the efficacy of immunotherapyIL18 drives bone marrow MDSC function to suppress T-cell activity and accelerate multiple myeloma.
23873689Ovarian CancinomaPromote immunity (T cell function)Interleukin (IL)-18 is an immune-enhancing cytokine, which induces IFN-γ production, T-helper 1 responses, and antitumor effects. Analysis of gene expression profiles revealed that IL18BP mRNA is increased in EOC tumors compared with normal ovary cells.
16049975Gastric CarcinomaInhibit immunityExploitation of interleukin-18 by gastric cancers for their growth and evasion of host immunity. Interleukin-18 (IL-18) is a pleiotropic cytokine that enhances Th1 or Th2 immune response. Our results indicate that gastric cancers exploit IL-18 to grow/invade and evade immunosurveillance in the hosts.
21724589MelanomaInhibit immunityIn this study, we show that low levels of circulating IL-18, either exogenous or tumor derived, act to suppress the NK cell arm of tumor immunosurveillance. IL-18 produced by tumor cells promotes the development of NK-controlled metastases in a PD-1-dependent manner. RNAi-mediated knockdown of IL-18 in tumors, or its systemic depletion by IL-18-binding protein, are sufficient to stimulate NK cell-dependent immunosurveillance in various tumor models.
18829492Metastatic Malignant Neoplasm in the LungInhibit immunity; Immunotherapy targetInterleukin (IL)-18 plays important roles in cancer progression and metastasis. IL-18bp-Fc had high and specific accumulation in the fLuc-4T1 lung metastasis tumor as evidenced by both PET and biodistribution studies. IL-18bp-Fc therapy can inhibit 4T1 breast cancer experimental lung metastasis.
23209317lymphomaPromote immunityIL-12/15/18-preactivated NK cells expressed high levels of IL-2Ralpha (CD25), and their rapid in vivo proliferation depended on IL-2 produced by CD4+ T cells. IL-12/15/18-preactivated NK cells accumulated in the tumor tissue and persisted at high cell numbers with potent effector function that required the presence of CD4+ T cells.
16998790MelanomaPromote immunityHere, we show that B16 melanoma cells actively modulate the interaction between DCs derived from bone marrow precursors and NK/LAK cells propagated from the spleen of C57BL/6 mice. DCs increased in a dose-dependent manner the ability of NK/LAK cells to kill melanoma cells and to produce cytokines. This activatory cross-talk entailed the production of IL-18 by DCs and of IFN-gamma by NK/LAK cells. Melanoma cells were not a passive target of NK activity; they regulated the outcome of the interaction between DCs and NK/LAK cells, inhibiting the in vitro production of cytokines as effectively as the genetic deletion of IL-18 or IFN-gamma.
Summary
SymbolIL18
Nameinterleukin 18
Aliases IGIF; IL1F4; IL-1g; IL-18; interferon-gamma-inducing factor; interleukin 18 (interferon-gamma-inducing facto ......
Chromosomal Location11q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL18 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL18
Nameinterleukin 18
Aliases IGIF; IL1F4; IL-1g; IL-18; interferon-gamma-inducing factor; interleukin 18 (interferon-gamma-inducing facto ......
Chromosomal Location11q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL18 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2610.656
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1350.937
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3570.774
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1380.734
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3180.736
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0930.937
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.480.331
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0610.351
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1720.892
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8560.652
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8460.77
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.310.04
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL18 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275905.1-5.10.549
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL18
Nameinterleukin 18
Aliases IGIF; IL1F4; IL-1g; IL-18; interferon-gamma-inducing factor; interleukin 18 (interferon-gamma-inducing facto ......
Chromosomal Location11q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL18. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL18
Nameinterleukin 18
Aliases IGIF; IL1F4; IL-1g; IL-18; interferon-gamma-inducing factor; interleukin 18 (interferon-gamma-inducing facto ......
Chromosomal Location11q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL18. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL18.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL18
Nameinterleukin 18
Aliases IGIF; IL1F4; IL-1g; IL-18; interferon-gamma-inducing factor; interleukin 18 (interferon-gamma-inducing facto ......
Chromosomal Location11q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL18. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL18
Nameinterleukin 18
Aliases IGIF; IL1F4; IL-1g; IL-18; interferon-gamma-inducing factor; interleukin 18 (interferon-gamma-inducing facto ......
Chromosomal Location11q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL18 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL18
Nameinterleukin 18
Aliases IGIF; IL1F4; IL-1g; IL-18; interferon-gamma-inducing factor; interleukin 18 (interferon-gamma-inducing facto ......
Chromosomal Location11q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL18 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL18
Nameinterleukin 18
Aliases IGIF; IL1F4; IL-1g; IL-18; interferon-gamma-inducing factor; interleukin 18 (interferon-gamma-inducing facto ......
Chromosomal Location11q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL18 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.